A review of the lipid-related effects of fluvastatin

被引：34

作者：

Liberopoulos, EN

Daskalopoulou, SS

Mikhailidis, DP

Wierzbicki, AS

Elisaf, MS ^{[1
]}

机构：

[1] Univ Ioannina, Dept Internal Med, Sch Med, GR-45110 Ioannina, Greece

[2] St Thomas Hosp, Dept Chem Pathol, London, England

[3] UCL Royal Free & Univ Coll Med Sch, Dept Clin Biochem, Vasc Dis Prevent Clin, London, England

来源：

CURRENT MEDICAL RESEARCH AND OPINION | 2005年 / 21卷 / 02期

关键词：

cholesterol; fluvastatin; HIV; lipids; pleiotropic effects; renal function; statins;

D O I：

10.1185/030079905X26261

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Statin therapy has been shown to significantly decrease vascular events and overall mortality in primary and secondary prevention trials. This review considers the pharmacology, non-lipid-lowering effects and clinical trial evidence of fluvastatin based on a survey of PubMed entries. Findings: Recent clinical data show that treatment with fluvastatin is associated with a variety of benefits in different high-risk populations along with a good safety profile. Fluvastatin exerts non-lipid lowering-associated pleiotropic effects in both clinical and experimental studies. Furthermore, an extended-release formulation of fluvastatin with a favourable pharmacokinetic profile is available. Conclusion. Treatment with fluvastatin offers a convenient, safe and evidence-based approach to managing dyslipidaemias and preventing vascular events.

引用

收藏

页码：231 / 243

页数：13

相关论文

共 169 条

[61] Effect of fluvastatin on cardiac outcomes in renal transplant recipients:: a multicentre, randomised, placebo-controlled trial [J].

Holdaas, H ;

Fellström, B ;

Jardine, AG ;

Holme, I ;

Nyberg, G ;

Fauchald, P ;

Grönhagen-Riska, C ;

Madsen, S ;

Neumayer, HH ;

Cole, E ;

Maes, B ;

Ambühl, P ;

Olsson, AG ;

Hartmann, A ;

Solbu, DO ;

Pedersen, TR .

LANCET, 2003, 361 (9374) :2024-2031

[62] Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial [J].

Holdaas, H ;

Jardine, AG ;

Wheeler, DC ;

Brekke, IB ;

Conlon, PJ ;

Fellstrom, B ;

Hammad, A ;

Holme, I ;

Isoniemi, H ;

Moore, R ;

Rowe, PA ;

Sweny, P ;

Talbot, DA ;

Wadstrom, J ;

Ostraat, O .

KIDNEY INTERNATIONAL, 2001, 60 (05) :1990-1997

[63]

Hunninghake DB, 2002, BR J CARDIOL, V9, P469

[64] Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: Studies in hypercholesterolernic and hypertensive patients [J].

Hussein, O ;

Shneider, J ;

Rosenblat, M ;

Aviram, M .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2002, 40 (01) :28-34

[65] Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL [J].

Hussein, O ;

Schlezinger, S ;

Rosenblat, M ;

Keidar, S ;

Aviram, M .

ATHEROSCLEROSIS, 1997, 128 (01) :11-18

[66] Long-term effects of statins on arterial pressure and stiffness of hypertensives [J].

Ichihara, A ;

Hayashi, M ;

Koura, Y ;

Tada, Y ;

Kaneshiro, Y ;

Saruta, T .

JOURNAL OF HUMAN HYPERTENSION, 2005, 19 (02) :103-109

[67] Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus [J].

Ichihara, A ;

Hayashi, M ;

Ryuzaki, M ;

Handa, M ;

Furukawa, T ;

Saruta, T .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (08) :1513-1517

[68] Pharmacokinetics and lipid-lowering effect of fluvastatin in hypercholesterolaernic patients on maintenance haemodialysis [J].

Ichimaru, N ;

Takahara, S ;

Moriyama, T ;

Kondo, M ;

Nonomura, N ;

Tanaka, T ;

Wang, JD ;

Imai, E ;

Okuyama, A ;

Kondo, Y .

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2004, 32 (01) :45-52

[69] Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells [J].

Ikeda, U ;

Shimpo, M ;

Ohki, R ;

Inaba, H ;

Takahashi, M ;

Yamamoto, K ;

Shimada, K .

HYPERTENSION, 2000, 36 (03) :325-329

[70] Fluvastatin reduces renal fibroblast proliferation and production of type III collagen: Therapeutic implications for tubulointerstitial fibrosis [J].

Ikeuchi, H ;

Kuroiwa, T ;

Yamashita, S ;

Hiramatsu, N ;

Maeshima, A ;

Kaneko, Y ;

Hiromura, K ;

Ueki, K ;

Nojima, Y .

NEPHRON EXPERIMENTAL NEPHROLOGY, 2004, 97 (04) :115-122

← 2 3 4 5 6 7 8 9 10 11 →